FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2073146211> ?p ?o ?g. }

• W2073146211 abstract "ST1481, a lead compound of a novel potent 7-substituted lipophilic camptothecin series, is able to overcome several mechanisms of drug resistance and was selected for clinical development. This study was designed to examine the antitumor activity of ST1481 in the treatment of preclinical models of human p53-defective hormone-refractory prostate carcinoma (DU145, PC3, and JCA-1) and to explore the cellular bases of the efficacy of camptothecins. A cellular pharmacology study (cytotoxicity, apoptosis, cellular drug accumulation, DNA damage, and cell cycle perturbation) was performed in DU145 and PC3 cells, characterized by a different cell cycle checkpoint status. The introduction of wild-type p53 in PC3 cells appreciably decreased the drug sensitivity. The 7-substituted camptothecins exhibited a high cytotoxic potency that paralleled their relative ability to induce DNA damage and a substantially increased cellular accumulation as compared to topotecan. The cytotoxic effect of camptothecins in DU145 cells was associated with arrest in S phase and early activation of apoptosis, whereas PC3 cells responded to drugs by a persistent block in G2 phase with a cytostatic effect and a late apoptosis. The efficiency of S phase checkpoint in DU145 cells was supported by a time-dependent decrease of DNA synthesis following treatment. In spite of an apparent cytostatic response and apoptosis resistance, the PC3 tumor was more responsive to in vivo treatment with camptothecins than the DU145 model. Indeed, the therapeutic outcome did not reflect the cell susceptibility to early activation of apoptosis. We suggest that cell death in PC3 cells is a delayed event consequent to persistent arrest in G2 and insufficient repair of DNA damage. ST1481 was appreciably more effective than topotecan in all tested tumors. In conclusion, the results indicated a relevant efficacy of camptothecins against human prostate carcinoma models, in spite of p53 alterations. Although p53 status could influence DNA damage and cell cycle checkpoints, p53 mutation was not a determinant of resistance. The results support that, in addition to the extent and persistence of topoisomerase I-mediated DNA damage, cell cycle checkpoints and DNA damage signaling pathways are critical determinants of tumor responsiveness to camptothecins. A role of cell cycle checkpoints activated by DNA damage in cell response is supported by the modulation of transcriptional profile." @default.
• W2073146211 created "2016-06-24" @default.
• W2073146211 creator A5002037450 @default.
• W2073146211 creator A5014481182 @default.
• W2073146211 creator A5021248234 @default.
• W2073146211 creator A5021257435 @default.
• W2073146211 creator A5033312783 @default.
• W2073146211 creator A5041620597 @default.
• W2073146211 creator A5045670524 @default.
• W2073146211 creator A5048820442 @default.
• W2073146211 creator A5049912464 @default.
• W2073146211 creator A5054112956 @default.
• W2073146211 creator A5071309513 @default.
• W2073146211 creator A5071824275 @default.
• W2073146211 creator A5075852039 @default.
• W2073146211 date "2003-04-01" @default.
• W2073146211 modified "2023-09-23" @default.
• W2073146211 title "Cellular bases of the antitumor activity of a 7-substituted camptothecin in hormone-refractory human prostate carcinoma models" @default.
• W2073146211 cites W113626925 @default.
• W2073146211 cites W1495853289 @default.
• W2073146211 cites W1510905532 @default.
• W2073146211 cites W1513102809 @default.
• W2073146211 cites W1593954725 @default.
• W2073146211 cites W1822517626 @default.
• W2073146211 cites W1831102019 @default.
• W2073146211 cites W1974135654 @default.
• W2073146211 cites W1985692894 @default.
• W2073146211 cites W1986010069 @default.
• W2073146211 cites W1992768693 @default.
• W2073146211 cites W1994773401 @default.
• W2073146211 cites W2016264010 @default.
• W2073146211 cites W2029925140 @default.
• W2073146211 cites W2031602769 @default.
• W2073146211 cites W2037685031 @default.
• W2073146211 cites W2037817195 @default.
• W2073146211 cites W2039252915 @default.
• W2073146211 cites W2048778747 @default.
• W2073146211 cites W2069159742 @default.
• W2073146211 cites W2070326852 @default.
• W2073146211 cites W2073796503 @default.
• W2073146211 cites W2075958941 @default.
• W2073146211 cites W2083833335 @default.
• W2073146211 cites W2088231104 @default.
• W2073146211 cites W2089750858 @default.
• W2073146211 cites W2090843842 @default.
• W2073146211 cites W2111680355 @default.
• W2073146211 cites W2119066973 @default.
• W2073146211 cites W2142468673 @default.
• W2073146211 cites W2415541861 @default.
• W2073146211 cites W2468886990 @default.
• W2073146211 doi "https://doi.org/10.1016/s0006-2952(03)00079-0" @default.
• W2073146211 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12694869" @default.
• W2073146211 hasPublicationYear "2003" @default.
• W2073146211 type Work @default.
• W2073146211 sameAs 2073146211 @default.
• W2073146211 citedByCount "18" @default.
• W2073146211 crossrefType "journal-article" @default.
• W2073146211 hasAuthorship W2073146211A5002037450 @default.
• W2073146211 hasAuthorship W2073146211A5014481182 @default.
• W2073146211 hasAuthorship W2073146211A5021248234 @default.
• W2073146211 hasAuthorship W2073146211A5021257435 @default.
• W2073146211 hasAuthorship W2073146211A5033312783 @default.
• W2073146211 hasAuthorship W2073146211A5041620597 @default.
• W2073146211 hasAuthorship W2073146211A5045670524 @default.
• W2073146211 hasAuthorship W2073146211A5048820442 @default.
• W2073146211 hasAuthorship W2073146211A5049912464 @default.
• W2073146211 hasAuthorship W2073146211A5054112956 @default.
• W2073146211 hasAuthorship W2073146211A5071309513 @default.
• W2073146211 hasAuthorship W2073146211A5071824275 @default.
• W2073146211 hasAuthorship W2073146211A5075852039 @default.
• W2073146211 hasConcept C105696609 @default.
• W2073146211 hasConcept C121608353 @default.
• W2073146211 hasConcept C126322002 @default.
• W2073146211 hasConcept C143425029 @default.
• W2073146211 hasConcept C147897179 @default.
• W2073146211 hasConcept C150903083 @default.
• W2073146211 hasConcept C154317977 @default.
• W2073146211 hasConcept C185592680 @default.
• W2073146211 hasConcept C190283241 @default.
• W2073146211 hasConcept C202751555 @default.
• W2073146211 hasConcept C207001950 @default.
• W2073146211 hasConcept C2776235491 @default.
• W2073146211 hasConcept C2776438761 @default.
• W2073146211 hasConcept C2779682216 @default.
• W2073146211 hasConcept C2779723316 @default.
• W2073146211 hasConcept C29537977 @default.
• W2073146211 hasConcept C31573885 @default.
• W2073146211 hasConcept C502942594 @default.
• W2073146211 hasConcept C552990157 @default.
• W2073146211 hasConcept C55493867 @default.
• W2073146211 hasConcept C71924100 @default.
• W2073146211 hasConcept C86803240 @default.
• W2073146211 hasConcept C98274493 @default.
• W2073146211 hasConceptScore W2073146211C105696609 @default.
• W2073146211 hasConceptScore W2073146211C121608353 @default.
• W2073146211 hasConceptScore W2073146211C126322002 @default.
• W2073146211 hasConceptScore W2073146211C143425029 @default.
• W2073146211 hasConceptScore W2073146211C147897179 @default.
• W2073146211 hasConceptScore W2073146211C150903083 @default.
• W2073146211 hasConceptScore W2073146211C154317977 @default.

• next